Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

ClinicalTrials.gov ID: NCT00085839

Public ClinicalTrials.gov record NCT00085839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Study of Single Agent Erlotinib [Tarceva (TM), OSI-774] Versus Standard Chemotherapy in Patients With Previously Untreated Advanced NSCLC and a Poor Performance Status

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.

Study identification

NCT ID
NCT00085839
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
OSI Pharmaceuticals
Industry
Enrollment
103 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2004 (Type not available)
Primary completion
Mar 2007 (Actual)
Completion
Mar 2007 (Actual)
Last update posted
Aug 9, 2012

2004 – 2007

United States locations

U.S. sites
19
U.S. states
12
U.S. cities
19
Facility City State ZIP Site status
California Cancer Care, Inc. Greenbrae California 94904 —
Sharp Clinical Oncology Research San Diego California 92123 —
Holy Cross Hospital Fort Lauderdale Florida 33308 —
University of Miami Miami Florida 33136 —
Mount Sinai Cancer Center Miami Beach Florida 33140 —
Evanston Northwestern Healthcare Evanston Illinois 60201 —
Oncology/Hematology Associates of Central Illinois Peoria Illinois 61615 —
Norton Healthcare, Inc. Louisville Kentucky 40202 —
Maryland Hematology/Oncology Associates Baltimore Maryland 21237 —
VA Sierra Nevada Health Care System Reno Nevada 89502 —
Weill Medical College of Cornell University New York New York 10021 —
FEK Addo, PC Bismarck North Dakota 58503 —
Gabrail Cancer Center Canton Ohio 44718 —
University Hospitals of Cleveland Cleveland Ohio 44106 —
Ohio State University Columbus Ohio 43210-1240 —
Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107 —
Charleston Hematology Oncology Charleston South Carolina 29403 —
East Tennessee Oncology/Hematology, PC Knoxville Tennessee 37920 —
Sarah Cannon Cancer Center Nashville Tennessee 37203 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00085839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 9, 2012 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00085839 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →